As compared with commercial PD‐L1 anti‐bodies, OTX as the small molecule epigenetic bromodomain inhibitor that could not only inhibit the interaction of PD‐1 and PD‐L1, but also suppress tumor cell proliferation, providing a potent alternative for immune checkpoint inhibitors. Here, CD274 is linked to neoplasm.